Shares of Cybin Inc. (OTCMKTS:CYBN – Get Free Report) were down 2.7% during mid-day trading on Thursday . The company traded as low as $0.25 and last traded at $0.26. Approximately 10,370,205 shares changed hands during mid-day trading, an increase of 119% from the average daily volume of 4,725,861 shares. The stock had previously closed at $0.26.
Analyst Ratings Changes
Separately, Bloom Burton restated a “buy” rating on shares of Cybin in a research note on Thursday, May 2nd.
View Our Latest Stock Report on CYBN
Cybin Trading Up 2.5 %
Institutional Investors Weigh In On Cybin
A hedge fund recently raised its stake in Cybin stock. Nadler Financial Group Inc. raised its position in Cybin Inc. (OTCMKTS:CYBN – Free Report) by 125.9% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 98,700 shares of the company’s stock after buying an additional 55,000 shares during the period. Nadler Financial Group Inc.’s holdings in Cybin were worth $41,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 17.94% of the company’s stock.
About Cybin
Cybin Inc, a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation.
Featured Articles
- Five stocks we like better than Cybin
- How to Effectively Use the MarketBeat Ratings Screener
- What’s Behind Walgreens Stock Plunge: What Investors Can Do Next
- What Are Dividends? Buy the Best Dividend Stocks
- MarketBeat Week in Review – 6/24 – 6/28
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- General Mills Stock Drops After Revenue Miss in Fiscal Q4 2024
Receive News & Ratings for Cybin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cybin and related companies with MarketBeat.com's FREE daily email newsletter.